Immune System Diseases Recruiting Phase 2 Trials for Benralizumab (DB12023)

Also known as: Immune System Disease

IndicationStatusPhase
DBCOND0029769 (Immune System Diseases)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03563066Effect of Benralizumab in Atopic DermatitisTreatment